Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus (NASDAQ:TARS) management will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Tuesday, November 11, 2025 at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast will be available and replays will be posted on the company's events page within 48 hours and archived for a limited time.

Tarsus (NASDAQ: TARS) reported third quarter 2025 results with $118.7 million of XDEMVY net product sales, up ~147% YoY, driven by >103,000 bottles delivered and weekly multi-patient prescribers growing ~30% vs Q2 2025. Coverage exceeds 90% across commercial, Medicare and Medicaid, with a gross-to-net discount of 44.7%. Net loss narrowed to $12.6 million (EPS $(0.30)) from $(23.4) million a year earlier. Cash, cash equivalents and marketable securities were $401.8 million at September 30, 2025. Pipeline and milestones include a Phase 2 TP-04 ocular rosacea study starting Dec 2025 (topline by year-end 2026) and a planned TP-05 Lyme prevention study in 2026. Management will host a conference call Nov 4, 2025 at 1:30 p.m. PT / 4:30 p.m. ET.

Tarsus (NASDAQ: TARS) will report third quarter 2025 financial results on Tuesday, November 4, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET to present results and a corporate update.

Participants may access the live webcast online; a recorded version will be posted on the company website shortly after the call and archived for approximately 90 days.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in two upcoming investor conferences in September 2025. Management will present at the Wells Fargo 20th Annual Healthcare Conference on September 3rd at 9:30 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 9th at 10:30 a.m. ET.

Investors can access live webcasts of both presentations through the events section of the Tarsus website. Replay recordings will be available within 48 hours and archived for a limited time.

Tarsus Pharmaceuticals (NASDAQ: TARS) reported record Q2 2025 financial results, achieving $102.7 million in net product sales for XDEMVY®, a 152% increase year-over-year. The company distributed approximately 91,000 bottles to patients during the quarter, with over 90% coverage across commercial, Medicare, and Medicaid lives.

The company's Direct-To-Consumer campaign has significantly boosted performance, with consumer awareness of XDEMVY more than tripling and website engagement up 400% since early 2025. More than 20,000 Eye Care Professionals are now prescribing XDEMVY, exceeding the company's target of 15,000.

Despite strong sales growth, Tarsus reported a net loss of $20.3 million ($0.48 per share) for Q2 2025, improved from a $33.3 million loss in Q2 2024. The company maintains a strong cash position of $381.1 million as of June 30, 2025.

Tarsus Pharmaceuticals (NASDAQ: TARS) has scheduled its second quarter 2025 financial results announcement and corporate update for Wednesday, August 6, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. Following the live presentation, a recorded version will be available on the company's website and remain accessible for approximately 90 days.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in three major upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 3rd at 6:00 AM PT, the Jefferies Global Healthcare Conference on June 4th at 12:45 PM PT, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 10:20 AM PT. Live webcasts will be available on Tarsus's website, with replays accessible within 48 hours and archived for a limited time.

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in three upcoming investor conferences in May 2025:

• Bank of America Securities 2025 Health Care Conference on May 13th at 6:40 PM ET
• H.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on May 20th at 3:00 PM ET
• Stifel Virtual Ophthalmology Forum on May 27th at 10:30 AM ET

Live webcasts will be available on the events section of Tarsus's website, with replays accessible within 48 hours and archived for a limited time.

Elanco Animal Health (NYSE: ELAN) has announced the sale of royalty and milestone rights for XDEMVY® (lotilaner ophthalmic solution) to Blackstone for $295 million in cash. The deal covers U.S. sales royalties from April 2025 through August 2033. The proceeds will be used to accelerate debt reduction, with Elanco expecting to achieve a net leverage ratio of 3.9x to 4.3x adjusted EBITDA by end-2025. The company will repay portions of outstanding term loans, reducing interest expense by approximately $10 million, offset by the sale of $10 million in royalties. XDEMVY, developed through Elanco's 2019 licensing agreement with Tarsus Pharmaceuticals, is the first FDA-approved medicine for Demodex blepharitis treatment. Elanco retains rights to non-U.S. royalties and future human applications of lotilaner beyond ophthalmic solutions.